Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1976 Feb;57(2):534–538. doi: 10.1172/JCI108308

7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate.

S A Jacobs, R G Stoller, B A Chabner, D G Johns
PMCID: PMC436681  PMID: 1062383

Abstract

Human subjects and rhesus monkeys receiving the antitumor agent methotrexate at the high dose levels recently introduced into clinical use (greater than 50 mg/kg) excrete significant amounts of the metabolite 7-hydroxymethotrexate. The metabolite is not detected in these species after methotrexate therapy at conventional dose levels. The evidence indicates that in primates, the in vivo conversion of methotrexate to 7-hydroxymethotrexate is a dose-dependent phenomenon, with the enzyme system(s) catalyzing the reaction having a low affinity for the drug.

Full text

PDF
534

Images in this article

537Image
on p.537

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BERTINO J. R., FISCHER G. A. TECHNIQUES FOR STUDY OF RESISTANCE TO FOLIC ACID ANTAGONISTS. Methods Med Res. 1964;10:297–307. [PubMed] [Google Scholar]
  2. Chabner B. A., Myers C. E., Coleman C. N., Johns D. G. The clinical pharmacology of antineoplastic agents (first of two parts). N Engl J Med. 1975 May 22;292(21):1107–1113. doi: 10.1056/NEJM197505222922107. [DOI] [PubMed] [Google Scholar]
  3. FREEMAN M. V. The fluorometric measurement of the absorption, distribution and excretion of single doses of 4-amino-10-methyl pteroylglutamic acid (amethopterin) in man. J Pharmacol Exp Ther. 1958 Jan;122(1):154–162. [PubMed] [Google Scholar]
  4. Henderson E. S., Adamson R. H., Denham C., Oliverio V. T. The metabolic fate of tritiated methotrexate. I. Absorption, excretion, and distribution in mice, rats, dogs and monkeys. Cancer Res. 1965 Aug;25(7):1008–1017. [PubMed] [Google Scholar]
  5. Henderson E. S., Adamson R. H., Oliverio V. T. The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man. Cancer Res. 1965 Aug;25(7):1018–1024. [PubMed] [Google Scholar]
  6. JOHNS D. G., HOLLINGSWORTH J. W., CASHMORE A. R., PLENDERLEITH I. H., BERTINO J. R. METHOTREXATE DISPLACEMENT IN MAN. J Clin Invest. 1964 Apr;43:621–629. doi: 10.1172/JCI104947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jaffe N., Frei E., 3rd, Traggis D., Bishop Y. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med. 1974 Nov 7;291(19):994–997. doi: 10.1056/NEJM197411072911902. [DOI] [PubMed] [Google Scholar]
  8. Jaffe N. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer. 1972 Dec;30(6):1627–1631. doi: 10.1002/1097-0142(197212)30:6<1627::aid-cncr2820300631>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  9. Johns D. G., Iannotti A. T., Sartorelli A. C., Booth B. A., Bertino J. R. The identity of rabbit-liver methotrexate oxidase. Biochim Biophys Acta. 1965 Aug 24;105(2):380–382. doi: 10.1016/s0926-6593(65)80164-3. [DOI] [PubMed] [Google Scholar]
  10. Zakrzewski S. F., Evans E. A., Phillips R. F. On the specificity of labeling in tritiated folic acid. Anal Biochem. 1970 Jul;36(1):197–206. doi: 10.1016/0003-2697(70)90348-9. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES